ERBB2 and breast carcinoma: Anti-HER2 therapy is well established in breast cancer, either in early-stage disease (as neoadjuvant or adjuvant therapy) or in an advanced stage; it is associated with an improved prognosis by increasing pathological complete response (pCR), disease-free survival (DFS), progression-free survival (PFS), and OS [13-17].